Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Synthorx, Inc.
In an interview, oncology development exec Peter Adamson reiterated the company’s view that THOR-707 is best-in-class, but more data are needed to see where its efficacy stands amid the IL-2 herd.
Sanofi R&D head John Reed says company has kept 95% of patients on its nearly 400 clinical trials and started 59 studies. Company has also stepped up collaborations and closed acquisitions, integrating employees remotely.
Another UK biotech has been swallowed up by a big pharma with Sanofi acquiring the Cambridge-based firm in a deal that could be worth almost $1.5bn.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
- Drug Discovery Tools
Drug Discovery Tools